Management of metastatic urothelial cancer: The role of surgery as an adjunct to chemotherapy

Robert S. Svatek, Arlene Siefker-Radtke, Colin P. Dinney

Producción científica: Review articlerevisión exhaustiva

26 Citas (Scopus)

Resumen

Metastatic or unresectable disease is identified in approximately 20% of patients presenting with invasive urothelial cancer. In addition, up to 50% of patients will develop metastases following radical cystectomy for clinically localized disease. Multiagent cisplatin-based chemotherapy is considered standard first-line treatment for these patients. Although urothelial cancer is considered a chemosensitive tumour, metastatic disease is associated with poor prognosis and short-term survival. Here, we review the role of a multidisciplinary approach to treating patients with metastatic urothelial cancer.

Idioma originalEnglish (US)
Páginas (desde-hasta)S228-S231
PublicaciónJournal of the Canadian Urological Association
Volumen3
N.º6 SUPPL. 4
EstadoPublished - 2009
Publicado de forma externa

ASJC Scopus subject areas

  • Oncology
  • Urology

Huella

Profundice en los temas de investigación de 'Management of metastatic urothelial cancer: The role of surgery as an adjunct to chemotherapy'. En conjunto forman una huella única.

Citar esto